Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.

Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Crisis' bitter pill for healthcare - Views on News from Equitymaster
  • E-MAIL
  • A  A  A
  • Oct 6, 2008

    Crisis' bitter pill for healthcare

    Bailout brings no cheer
    Asian stocks are trading deep in the red today. Stocks in Hong Kong, Japan, Korea and China are facing the severest pressure today. Benchmark indices there are down anywhere between 2% and 4%. Deepening of credit crisis in Europe and weak employment data from the US are said to be reasons for today's decline in Asian stocks. As reported by Bloomberg, 159,000 jobs were lost in the US in September, the most in five years.

    Around 1.1 m jobs were created last year in the US. 760,000 have been lost in the first nine months of this year. The biggest decline has been recorded in the financial services space, which has seen the demise of behemoths like Bear Stearns and Lehman Brothers.

    In the meanwhile, the financial bailout plan in its new avatar was cleared by the US House of Representatives (the lower house of US Parliament, like India's Lok Sabha) last Friday. This clearance came after a couple of weeks of contentious debate on the impact of the plan on taxpayers. CNN's financial website mentions that 'the law, which allows the Treasury Secretary to purchase as much as US$ 700 bn in troubled assets in a bid to kick-start lending, ushers in one of the most far-reaching interventions in the economy since the Great Depression."

    Crisis' bitter pill for healthcare
    The impact of financial crisis in the US and Europe is now being felt in sectors far and wide. Healthcare is the latest example. Bloomberg and a leading business daily reports that India's leading pharmaceutical company Dr. Reddy's is facing delays in the much-awaited launch of its diabetes drug called Balaglitazone. This is because Rheoscience A/S, the Danish firm conducting clinical trials on it has run into financial problems.

    However no all hopes are lost for Dr. Reddy's as Rheoscience's parent company Nordic Bioscience is likely to take over the trials if the former ends up being liquidated. Importantly, Balaglitazone is a drug considered the closest to being launched by any Indian pharmaceutical company. The drug is intended to be used in treatment of type-2 diabetes, a rising ailment among urban Indians.

    As mentioned on the website of the International Diabetes Federation, lifestyle diseases like diabetes (type-1 and type-2) and heart diseases are expected to put a heavy burden on the economies worldwide. The cost on India alone is estimated at US$ 333 bn over the next 10 years.

    But there's something deadlier than diabetes
    Violence, it is. As per a study published by the Pan American Journal of Public Health, violence causes US$ 150 bn in annual economic losses worldwide, more than the losses on account of diseases like diabetes and malaria. According to a study, violence is a major drag on developing economies. Suicides and murders (homicides) account for 54% and 35% respectively of the 1.6 m victims of violence. The remaining 11% deaths are on account of violence inflicted by larger groups such as organised political groups and terrorist organisations.

    India contributes to 21% of worldwide suicides and 10% of homicides, making the country among the worst sufferers of violence.



    Equitymaster requests your view! Post a comment on "Crisis' bitter pill for healthcare". Click here!


    More Views on News

    How to Ride Alongside India's Best Fund Managers (The 5 Minute Wrapup)

    Jun 10, 2017

    Forty Indian investing gurus, as worthy of imitation as the legendary Peter Lynch, can help you get rich in the stock market.

    You've Heard of Timeless Books... Ever Heard of Timeless Stocks? (The 5 Minute Wrapup)

    Aug 19, 2017

    Ever heard of Lindy Effect? Find out how you can use it to pick timeless stocks.

    Why NOW Is the WORST Time for Index Investing (The 5 Minute Wrapup)

    Aug 18, 2017

    Buying the index now will hardly help make money in stocks even in ten years.

    Trump Takes a Beating (Vivek Kaul's Diary)

    Aug 18, 2017

    Donald J Trump, a wrasslin' fan, took a 'Holy Sh*t!' blow on Tuesday.

    How To Read Your Mutual Fund Account Statement Correctly (Outside View)

    Aug 17, 2017

    PersonalFN simplifies the mutual fund account statement for you.

    More Views on News

    Most Popular

    Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

    Aug 7, 2017

    The data tells us quite a different story from the one the government is trying to project.

    A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

    Aug 10, 2017

    Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

    Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

    Aug 8, 2017

    Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

    Signs of Life in the India VIX(Daily Profit Hunter)

    Aug 12, 2017

    The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

    7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

    Aug 7, 2017

    Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

    Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
    Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

    LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.

    SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

    Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
    Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407

    Become A Smarter Investor In
    Just 5 Minutes

    Multibagger Stocks Guide 2017
    Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
    We will never sell or rent your email id.
    Please read our Terms


    Aug 18, 2017 (Close)